Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose (MTD), dose limiting
toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid
leukemia (AML).